mkp10241
Safety and Tolerability
Mankind Pharma LimitedPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
1 Active assets in the Safety and Tolerability cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Heplisav-B National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | B |
Zoster Vaccine Recombinant, Adjuvanted National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | B |
Capivasertib AstraZeneca | Phase 1 | CC |
Selvigaltin Galecto Biotech AB | Phase 1 | CC |
zp7570 Zealand Pharma | Phase 1 | CC |
Same molecule, other indications
mkp10241 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →